Exagen (XGN) Competitors $11.92 +0.38 (+3.29%) Closing price 04:00 PM EasternExtended Trading$11.61 -0.31 (-2.63%) As of 04:40 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock XGN vs. FTRE, PNTG, CDNA, INNV, FLGT, CSTL, PSNL, AIRS, AUNA, and TALKShould you be buying Exagen stock or one of its competitors? The main competitors of Exagen include Fortrea (FTRE), The Pennant Group (PNTG), CareDx (CDNA), InnovAge (INNV), Fulgent Genetics (FLGT), Castle Biosciences (CSTL), Personalis (PSNL), AirSculpt Technologies (AIRS), Auna (AUNA), and Talkspace (TALK). These companies are all part of the "healthcare" industry. Exagen vs. Its Competitors Fortrea The Pennant Group CareDx InnovAge Fulgent Genetics Castle Biosciences Personalis AirSculpt Technologies Auna Talkspace Fortrea (NASDAQ:FTRE) and Exagen (NASDAQ:XGN) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, valuation, dividends, media sentiment, profitability, analyst recommendations, institutional ownership and risk. Do insiders and institutionals hold more shares of FTRE or XGN? 75.3% of Exagen shares are held by institutional investors. 0.4% of Fortrea shares are held by company insiders. Comparatively, 12.6% of Exagen shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Do analysts recommend FTRE or XGN? Fortrea currently has a consensus target price of $12.17, suggesting a potential upside of 25.56%. Exagen has a consensus target price of $12.60, suggesting a potential upside of 5.70%. Given Fortrea's higher possible upside, research analysts clearly believe Fortrea is more favorable than Exagen.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Fortrea 2 Sell rating(s) 9 Hold rating(s) 1 Buy rating(s) 2 Strong Buy rating(s) 2.21Exagen 1 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 2.78 Does the media prefer FTRE or XGN? In the previous week, Fortrea had 13 more articles in the media than Exagen. MarketBeat recorded 15 mentions for Fortrea and 2 mentions for Exagen. Exagen's average media sentiment score of 0.62 beat Fortrea's score of 0.59 indicating that Exagen is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Fortrea 0 Very Positive mention(s) 2 Positive mention(s) 10 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Exagen 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more volatility & risk, FTRE or XGN? Fortrea has a beta of 1.81, suggesting that its share price is 81% more volatile than the S&P 500. Comparatively, Exagen has a beta of 1.54, suggesting that its share price is 54% more volatile than the S&P 500. Which has higher valuation & earnings, FTRE or XGN? Exagen has lower revenue, but higher earnings than Fortrea. Exagen is trading at a lower price-to-earnings ratio than Fortrea, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioFortrea$2.70B0.33-$328.50M-$11.38-0.85Exagen$55.64M4.71-$15.11M-$0.89-13.39 Is FTRE or XGN more profitable? Exagen has a net margin of -28.85% compared to Fortrea's net margin of -37.57%. Fortrea's return on equity of 5.25% beat Exagen's return on equity.Company Net Margins Return on Equity Return on Assets Fortrea-37.57% 5.25% 1.72% Exagen -28.85%-130.38%-34.69% SummaryExagen beats Fortrea on 9 of the 17 factors compared between the two stocks. Get Exagen News Delivered to You Automatically Sign up to receive the latest news and ratings for XGN and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding XGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart XGN vs. The Competition Export to ExcelMetricExagenMED PRODUCTS IndustryMedical SectorNASDAQ ExchangeMarket Cap$262.24M$10.31B$6.05B$10.51BDividend YieldN/A1.89%5.73%4.80%P/E Ratio-13.3920.5185.3627.35Price / Sales4.7131.97516.10196.40Price / CashN/A25.0637.5761.53Price / Book22.073.4812.426.82Net Income-$15.11M$208.83M$3.32B$276.80M7 Day Performance8.56%-0.26%0.97%0.26%1 Month Performance28.03%3.76%10.70%8.29%1 Year Performance341.48%-3.96%76.19%35.59% Exagen Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)XGNExagen3.8565 of 5 stars$11.92+3.3%$12.60+5.7%+327.4%$262.24M$55.64M-13.39220Analyst ForecastFTREFortrea3.1655 of 5 stars$9.77+1.9%$11.72+20.0%-48.2%$884.85M$2.73B-0.8615,500PNTGThe Pennant Group3.8775 of 5 stars$25.45-1.6%$34.40+35.2%-30.8%$879.22M$798.92M32.617,000Analyst ForecastCDNACareDx4.5363 of 5 stars$14.97+0.1%$25.50+70.4%-54.2%$796.81M$340.83M14.68740Analyst DowngradeINNVInnovAge0.4541 of 5 stars$5.25+4.9%$5.00-4.8%-2.4%$704.64M$853.70M-22.592,440News CoverageFLGTFulgent Genetics3.5982 of 5 stars$23.16+1.6%$25.33+9.4%+10.0%$700.66M$283.47M-13.791,313News CoverageCSTLCastle Biosciences2.3422 of 5 stars$23.20+2.1%$37.00+59.5%-34.7%$681.54M$346.27M-67.13540PSNLPersonalis3.0724 of 5 stars$7.39+2.7%$7.42+0.3%+79.9%$651.07M$80.32M-5.74400AIRSAirSculpt Technologies0.8954 of 5 stars$8.24+6.5%$3.75-54.5%+73.1%$513.26M$180.35M-32.88240News CoverageAnalyst ForecastGap UpAUNAAuna3.9057 of 5 stars$6.72-0.8%$10.70+59.3%-4.9%$497.44M$4.33B7.6414,842News CoverageAnalyst ForecastTALKTalkspace3.768 of 5 stars$2.83flat$4.50+59.0%+19.1%$475.61M$202.61M142.07500Positive News Related Companies and Tools Related Companies FTRE Alternatives PNTG Alternatives CDNA Alternatives INNV Alternatives FLGT Alternatives CSTL Alternatives PSNL Alternatives AIRS Alternatives AUNA Alternatives TALK Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:XGN) was last updated on 10/15/2025 by MarketBeat.com Staff From Our PartnersURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredBitcoin grabs headlines, but smart money likes this tokenBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | SponsoredGold surges past $3,600 … but this has beat gold by 1,000xGold has surged past $3,600 an ounce — up 45% in the past year — but one veteran metals analyst says the real ...Weiss Ratings | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredArizona-made nanochips the new millionaire maker?George Gilder handed President Reagan the first microchip that helped create $6.5 trillion in wealth over the ...Banyan Hill Publishing | SponsoredBuy UBER immediatelyBULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Exagen Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Exagen With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
